Your session is about to expire
← Back to Search
Small Molecule Drug
AMG 510 for Non-Small Cell Lung Cancer
Phase 1 & 2
Waitlist Available
Led By Wade Iams, MD, MSCI
Research Sponsored by Criterium, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18.5 months
Awards & highlights
Study Summary
This trial will test a new cancer drug on people with advanced lung cancer that has spread to the brain.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18.5 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18.5 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Dose Exploration
Secondary outcome measures
Dose Expansion
Side effects data
From 2022 Phase 1 trial • 20 Patients • NCT0488706414%
Constipation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Normal Hepatic Function
Moderate Hepatic Impairment
Severe Hepatic Impairment
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dose ExpansionExperimental Treatment2 Interventions
AMG 510/MVASI
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 510
2020
Completed Phase 1
~120
Find a Location
Who is running the clinical trial?
Criterium, Inc.Lead Sponsor
16 Previous Clinical Trials
774 Total Patients Enrolled
AmgenIndustry Sponsor
1,383 Previous Clinical Trials
1,379,921 Total Patients Enrolled
Wade Iams, MD, MSCIPrincipal InvestigatorVanderbilt University Medical Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You may be eligible for the study if you have had other types of cancer in the past, but only if they are not expected to affect your overall health and if you have been free of those cancers for at least 3 years. The principal investigator will review your case to determine if you can participate.You have previously taken AMG-510, other drugs that target the KRAS G12C mutation, or VEGF inhibitors for treating lung cancer.You have been diagnosed with another type of cancer in the past 2 years.You may still qualify for the study if you have non-melanoma skin cancer, cervical cancer in-situ, well-differentiated thyroid cancer, or prostate cancer.
Research Study Groups:
This trial has the following groups:- Group 1: Dose Expansion
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger